Eui Hwan Cho

This inventor holds 4 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Samjin Pharmaceutical Co., Ltd., Astech. Co., Ltd., Bamichem Co., Ltd.. Active years: 1998-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eui Hwan Cho. Retrieved from https://idiyas.com/inventor/eui-hwan-cho-udrk3ivm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 2)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 7.5

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

3 out of 13

Samjin Pharmaceutical Co., Ltd.

Incheon University Industry Academic Cooperation Foundation

patents

5. 1 out of 2

Samjin Pharm. Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 1998-2023

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11712414 - Oral pharmaceutical composition for preventing or treating dry eye syndrome comprising rebamipide or a prodrug thereof (2023-08-01),

2. 11420963 - Rebamipide prodrugs, preparation method and use thereof (2022-08-23),

3. 10844062 - Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof (2020-11-24),

4. 5747521 - N-cinnamoyl-2-methyl-5-methoxy-3-indoleacetic acid ester, and (1998-05-05),

Title: Innovator in Pharmaceutical Advances: Eui Hwan Cho

Introduction

Eui Hwan Cho, an esteemed inventor based in Seoul, South Korea, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of four patents. His innovative work focuses primarily on formulations that provide effective treatment options for various health conditions, showcasing his dedication to improving patient care.

Latest Patents

Among Cho's latest patents is an oral pharmaceutical composition designed to prevent or treat dry eye syndrome. This composition comprises rebamipide or a prodrug thereof, offering a safe and convenient alternative to conventional eye drops. This advancement allows patients to manage dry eye syndrome through oral treatment methods. Another notable patent pertains to a novel rebamipide prodrug with a significantly increased absorption rate—25 times greater than that of rebamipide itself. This prodrug formulation holds promise for treating a variety of ailments, including gastric ulcers, acute and chronic gastritis, xerophthalmia, cancer, osteoarthritis, rheumatoid arthritis, and obesity.

Career Highlights

Eui Hwan Cho's career is marked by his pivotal roles in reputable companies such as Samjin Pharmaceutical Co., Ltd. and Astech Co., Ltd. His contributions in these organizations have solidified his reputation as a forward-thinking innovator in the pharmaceutical industry. His expertise has led to groundbreaking developments that enhance the effectiveness of treatment methodologies.

Collaborations

Throughout his career, Cho has collaborated with talented colleagues, including Hee Jong Shin and Ho Seok Kwon. These partnerships have not only fostered a collaborative environment but have also contributed to the inventive processes leading to the successful patents that define his career.

Conclusion

Eui Hwan Cho represents a beacon of innovation in the pharmaceutical sector, with patents that not only demonstrate his inventiveness but also reflect a commitment to advancing medical treatments. His work continues to inspire future innovations and holds promise for better health outcomes for patients worldwide.

Profile summary based on public USPTO records.